RGLS Share Price

Open 1.10 Change Price %
High 1.11 1 Day -0.03 -2.73
Low 1.05 1 Week -0.13 -10.83
Close 1.07 1 Month -1.18 -52.44
Volume 774588 1 Year -5.94 -84.74
52 Week High 8.90
52 Week Low 1.05
RGLS Important Levels
Resistance 2 1.13
Resistance 1 1.10
Pivot 1.08
Support 1 1.04
Support 2 1.01
NASDAQ USA Most Active Stocks
CTRP 47.59 1.13%
ADBE 119.47 -0.13%
FSLR 33.57 -8.33%
FSLR 33.57 -8.33%
CERN 55.37 0.18%
BIDU 186.01 0.21%
AAPL 137.11 0.30%
AAPL 137.11 0.30%
FB 136.12 1.79%
MASI 87.05 2.03%
More..
NASDAQ USA Top Gainers Stocks
VALV 0.05 66.67%
LOCM 0.09 50.00%
BASI 1.33 31.68%
WRES 0.09 28.57%
INAP 2.31 27.62%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
AETI 2.40 23.08%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
LIWA 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Regulus Therapeutics Inc. (NASDAQ: RGLS)

RGLS Technical Analysis 5
As on 22nd Feb 2017 RGLS Share Price closed @ 1.07 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.79 & Strong Sell for SHORT-TERM with Stoploss of 2.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
RGLS Target for February
1st Target up-side 2.04
2nd Target up-side 2.64
3rd Target up-side 3.23
1st Target down-side 0.36
2nd Target down-side -0.24
3rd Target down-side -0.83
RGLS Other Details
Segment EQ
Market Capital 170651968.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
RGLS Address
RGLS
N/A
RGLS Latest News
Interactive Technical Analysis Chart Regulus Therapeutics Inc. ( RGLS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Regulus Therapeutics Inc.
RGLS Business Profile
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. As of December 31, 2012 , the Company�s operations included acquiring and in-licensing intellectual property rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs. The Company is developing RG-101 for the treatment of HCV and is advancing other microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis and metabolic diseases.